Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: A cohort study

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Sakaguchi, Yusuke ^a   Fujii, Naohiko ^b   Shoji, Tatsuya ^c   Hayashi, Terumasa ^c   Rakugi, Hiromi ^a   Iseki, Kunitoshi ^b   Tsubakihara, Yoshiharu ^b   Isaka, Yoshitaka ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Scientific Academic Committee of the Japanese Society for Dialysis Therapy   (Japan)

^c OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM; PHOSPHATE;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; FEMALE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; RISK ASSESSMENT; RISK REDUCTION; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; MORTALITY; ODDS RATIO; RENAL REPLACEMENT THERAPY; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; HYPERPHOSPHATEMIA; MAGNESIUM; MALE; ODDS RATIO; PHOSPHATES; RENAL DIALYSIS; RISK FACTORS;

EID: 84919935844     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116273     Document Type: Article

References (31)

1. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. (2009) Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases.
2. Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, et al. (2012) Overview of regular dialysis treatment in Japan (as of 31 December 2009). Ther Apher Dial 16: 11-53.
3. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, et al. (2009) Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302: 1782-1789
4. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(Suppl 3): S112-S119
5. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, et al. (2008) Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3: 505-521
6. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, et al. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218
7. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, et al. (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52: 519-530
8. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, et al. (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953
9. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, et al. (2005) Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 16: 2778-2788
10. Ayus JC, Achinger SG, Mizani MR, Chertow GM, Furmaga W, et al. (2007) Phosphorus balance and mineral metabolism with 3 h daily hemodialysis. Kidney Int 71: 336-342
11. Maier JA (2012) Endothelial cells and magnesium: implications in atherosclerosis. Clin Sci (Lond) 122: 397-407
12. Qu X, Jin F, Hao Y, Zhu Z, Li H, et al. (2013) Magnesium and the risk of cardiovascular events: a metaanalysis of prospective cohort studies. PLoS One 8: e57720
13. Larsson SC, Orsini N, Wolk A (2012) Dietary magnesium intake and risk of stroke: a meta-analysis of prospective studies. Am J Clin Nutr 95: 362-366
14. Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, et al. (2013) Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr 98: 160-173
15. Kanbay M, Yilmaz MI, Apetrii M, Saglam M, Yaman H, et al. (2012) Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol 36: 228-237
16. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, et al. (2014) Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 85: 174-181.
17. Massy ZA, Drueke TB (2012) Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J 5(suppl 1): i52-i61.
18. Van Laecke S, Van Biesen W, Vanholder R (2012) Hypomagnesaemia, the kidney and the vessels. Nephrol Dial Transplant 27: 4003-4010.
19. Hruby A, O'Donnell CJ, Jacques PF, Meigs JB, Hoffmann U, et al. (2014) Magnesium intake is inversely associated with coronary artery calcification: the Framingham Heart Study. JACC Cardiovasc Imaging 7: 59-69.
20. Tzanakis I, Pras A, Kounali D, Mamali V, Kartsonakis V, et al. (1997) Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium. Nephrol Dial Transplant 12: 2036-2037
21. Ishimura E, Okuno S, Kitatani K, Tsuchida T, Yamakawa T, et al. (2007) Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 68: 222-227
22. Montezano AC, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, et al. (2010) Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 56: 453-462
23. Kircelli F, Peter ME, Sevinc Ok E, Celenk FG, Yilmaz M, et al. (2012) Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant 27: 514-521
24. Louvet L, Büchel J, Steppan S, Passlick-Deetjen J, Massy ZA (2013) Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant 28: 869-878
25. Montes de Oca A, Guerrero F, Martinez-Moreno JM, Madueño JA, Madueño JA, Herencia C, et al. (2014) Magnesium Inhibits Wnt/b-Catenin Activity and Reverses the Osteogenic Transformation of Vascular Smooth Muscle Cells. PLoS One 9: e89525
26. Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, et al. (2012) An overview of regular dialysis treatment in Japan (as of 31 December 2010). Ther Apher Dial 16: 483-521
27. Kroll MH, Elin RJ (1985) Relationships between magnesium and protein concentrations in serum. Clin Chem 31: 244-246
28. Wyskida K, Witkowicz J, Chudek J, Wiecek A (2012) Daily magnesium intake and hypermagnesemia in hemodialysis patients with chronic kidney disease. J Ren Nutr 22: 19-26.
29. D'Haese PC, Couttenye MM, Lamberts LV, Elseviers MM, Goodman WG, et al. (1999) Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of endstage renal failure patients. Clin Chem 45: 1548-1556
30. Covic A, Passlick-Deetjen J, Kroczak M, Büschges-Seraphin B, Ghenu A, et al. (2013) A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant 28: 2383-2392
31. Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernández-Martín JL, et al. (2011) Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 26: 1938-1947